This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class TNM002; Huadao Biopharma launching a STAR Market IPO process with its low-cost CAR-T therapy for relapsed non-Hodgkin lymphoma; and Sirius Therapeutics resubmitting a Hong Kong IPO for siRNA therapies focused on FXI anticoagulants. Maxwell Biosciences received approval for an A+H dual listing with its ADC platform targeting advanced cancers, while Earendil Labs plans a Hong Kong IPO to expand its AI-driven drug development in oncology and autoimmune diseases. Key approvals include GSK’s depemokimab for asthma and nasal polyps, Abbisko Therapeutics’ Ipagratinib gaining EMA Orphan Drug Designation for HCC, Akeso reporting strong NSCLC data for ivonescimab, and Foshan Radiopharmaceutical securing NMPA approval for its novel lung cancer diagnostic. 

 

Read the full article on the Selesta website